Estados Unidos · Revistas de economía · Institutional Investor

Biopharma’s Sickly September

Publicado por Institutional Investor · Estados Unidos hace 6 d

September was a rough month for prominent biopharma and life sciences hedge funds.Many lost money, some by double-digit percentage rates. As a result, quite a few funds are up…

Leer el artículo completo en Institutional Investor Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.institutionalinvestor.com)

Biopharma’s Sickly September

También te puede interesar

Think Being a Night Owl Is Just a Sleep Preference? Researchers Link It to a Depression Subtype

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Fervo Energy Company Investors to Inquire About Securities Class Action Investigation - FRVO

Can a Roth Conversion Wait if You're 5-10 Years From Retiring?

Look up tonight: October’s full moon is for hunters

Millennials are having their midlife career crisis

Carson Hocevar Is Telling NASCAR Fans To Vote For Somebody Else

Biopharma’s Sickly September

Compartir

También te puede interesar

Think Being a Night Owl Is Just a Sleep Preference? Researchers Link It to a Depression Subtype

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Fervo Energy Company Investors to Inquire About Securities Class Action Investigation - FRVO

Can a Roth Conversion Wait if You're 5-10 Years From Retiring?

Look up tonight: October’s full moon is for hunters

Millennials are having their midlife career crisis

Carson Hocevar Is Telling NASCAR Fans To Vote For Somebody Else